FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. [electronic resource]
Producer: 20070912Description: 3712-8 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antibody-Dependent Cell Cytotoxicity
- Antineoplastic Agents -- adverse effects
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- ErbB Receptors -- metabolism
- Female
- Genotype
- Humans
- Male
- Middle Aged
- Polymorphism, Genetic
- Receptors, IgG -- genetics
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.